Doctors prescribe Rinvoq (upadacitinib) to treat certain inflammatory conditions, such as rheumatoid arthritis (RA) and ulcerative colitis (UC). It’s available as an extended-release oral tablet and ...
AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...
I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
AbbVie settles with generic Rinvoq hopefuls, shielding the immunology med's US stronghold until 2037
With Rinvoq and its sibling medicine Skyrizi having successfully picked up the sales torch in the wake of Humira’s tumble over the patent cliff, AbbVie is working to cover its legal bases so the ...
Erica Andersen and Christopher Sipes, co-chairs of Covington’s patent litigation group, and co-counsel David Frazier, the global vice chair of Latham’s intellectual property litigation practice, ...
For the second time in the last three weeks, AbbVie has revealed successful results from a phase 3 study of Rinvoq as a treatment for the hair-loss disease alopecia areata (AA). The second replicate ...
Shares of AbbVie ABBV rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for ...
AbbVie ABBV delivered encouraging second-quarter 2025 results last week, sending a clear message — it is effectively managing its post-Humira transition. The stronger-than-expected sales of newer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback